Emergent BioSolutions (NYSE:EBS) Cut to Hold at StockNews.com

StockNews.com cut shares of Emergent BioSolutions (NYSE:EBS) from a buy rating to a hold rating in a research report sent to investors on Wednesday morning.

EBS has been the topic of a number of other reports. Benchmark boosted their target price on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Rodman & Renshaw reaffirmed a “buy” rating and set a $16.00 price objective on shares of Emergent BioSolutions in a report on Friday, September 13th.

Emergent BioSolutions Stock Performance

Shares of NYSE EBS opened at $9.48 on Wednesday. The company has a market cap of $513.36 million, a P/E ratio of -2.31 and a beta of 1.57. Emergent BioSolutions has a 52-week low of $1.42 and a 52-week high of $15.10. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The firm’s fifty day moving average is $8.75 and its two-hundred day moving average is $8.18.

Institutional Trading of Emergent BioSolutions

Hedge funds have recently made changes to their positions in the business. CWM LLC increased its stake in Emergent BioSolutions by 32,706.7% during the second quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 4,906 shares during the last quarter. Meeder Asset Management Inc. bought a new position in shares of Emergent BioSolutions during the 2nd quarter valued at approximately $41,000. Verus Capital Partners LLC purchased a new stake in Emergent BioSolutions during the 2nd quarter valued at $68,000. Stifel Financial Corp bought a new stake in Emergent BioSolutions in the third quarter worth $96,000. Finally, FORA Capital LLC purchased a new position in Emergent BioSolutions during the third quarter worth $103,000. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.